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Abstract Objective: To test the
hypothesis that extracorporeal ther-
apy with polymyxin B (PMX-B) may
prevent Gram-negative sepsis-
induced acute renal failure (ARF) by
reducing the activity of proapoptotic
circulating factors. Setting: Medi-
cal-Surgical Intensive Care Units.
Patients and interventions: Sixteen
patients with Gram-negative sepsis
were randomized to receive standard
care (Surviving Sepsis Campaign
guidelines) or standard care plus
extracorporeal therapy with PMX-B.
Measurements and results: Cell
viability, apoptosis, polarity, mor-
phogenesis, and epithelial integrity
were evaluated in cultured tubular
cells and glomerular podocytes incu-
bated with plasma from patients of
both groups. Renal function was
evaluated as SOFA and RIFLE
scores, proteinuria, and tubular
enzymes. A signiﬁcant decrease of
plasma-induced proapoptotic activity
was observed after PMX-B treatment
on cultured renal cells. SOFA and
RIFLE scores, proteinuria, and urine
tubular enzymes were all signiﬁcantly
reduced after PMX-B treatment. Loss
of plasma-induced polarity and per-
meability of cell cultures was
abrogated with the plasma of patients
treated with PMX-B. These results
were associated to a preserved
expression of molecules crucial for
tubular and glomerular functional
integrity. Conclusions: Extracorpo-
real therapy with PMX-B reduces the
proapoptotic activity of the plasma of
septic patients on cultured renal cells.
These data conﬁrm the role of apop-
tosis in the development of sepsis-
related ARF.
Keywords Sepsis  Acute renal
failure  Lipopolysaccharide 
Apoptosis
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Acute renal failure (ARF) occurs in 20% of patients with
severe sepsis and in the 50% of patients with septic shock
[1, 2]. The combination of ARF and sepsis is associated
with a 70% mortality rate as compared with a 45%
mortality rate in patients with ARF alone [1, 2].
Experimental [3–5] and clinical [6] studies suggested
that circulating lipopolysaccharide (LPS), a cell wall
component of Gram-negative bacteria, is the key element
of the sepsis-induced ARF [7]. Direct hemoperfusion
through a column of immobilized polymyxin B (PMX-B)
to reduce plasma levels of LPS [8–10] has been therefore
proposed to improve hemodynamics and oxygenation
[11] and prevent ARF [12].
Apoptosis, an energy-dependent process whereby cells
carry out programmed death [13], contributes to the
pathogenesis of ARF [14]. Recently, Jo et al. [4] and
Bordoni et al. [15] suggested that Fas-mediated and cas-
pase-mediated apoptosis of tubular cells might be one of
the possible mechanisms involved in the endotoxemia-
induced renal dysfunction. Consistent with these ﬁndings,
several studies have shown that circulating LPS may
cause an inappropriate activation of proapoptotic path-
ways in immune, epithelial, and endothelial cells [6, 16,
17]. Moreover, LPS can directly act on kidney-resident
cells such as podocytes and tubular epithelium, stimulat-
ing the synthesis of inﬂammatory mediators [18–20].
The present study was designed to test the hypothesis
that extracorporeal therapy with PMX-B may prevent
Gram-negative sepsis-induced ARF by reducing the
activity of proapoptotic circulating factors on tubular cells
and glomerular podocytes. The primary outcome variable
was viability of renal cell cultures exposed to the plasma
of septic patients. Secondary outcome variables were
different markers of renal function. Parts of these data
were published as an abstract [21].
Methods
Patients admitted to the intensive care units of the Moli-
nette (University of Turin) and Niguarda (Milan)
hospitals were recruited between January 2006 and April
2007. Ethics committees approved the protocol and
written informed consent was obtained from all patients.
A detailed version of the methods is available in the
Electronic Supplementary Material (ESM).
Patients and treatments
Patients were eligible to participate in the study if they
had a positive culture for Gram-negative bacteria and
randomization could be performed within 24 h of
matching study criteria. Inclusion criteria were as follows:
(1) three of the systemic inﬂammatory response system
(SIRS) and (2) presence of one organ dysfunction [22,
23]. Exclusion criteria were as follows: (1) presence of
two or more failing organs; life expectancy B 30 days;
(2) presence of a ‘‘do not resuscitate’’ order; (3) HIV
infection; (4) uncontrolled hemorrhage within 24 h before
study entry; (5) organ transplantation during the year
before study entry; (6) history of sensitivity to polymyxin-
B or anticoagulant and/or extracorporeal circulation; (7)
severe thrombocytopenia (\30,000 cells/mm
3) and/or
granulocytopenia (\500 cells/mm
3); (8) an acute physi-
ology and chronic health evaluation (APACHE) II
score[30 [23].
Patients were randomized to receive conventional
treatments according to the Surviving Sepsis Campaign
guidelines [24] (CONV group) or to undergo, in addition
to standard care, a hemoperfusion session with Poly-
myxin-B Fiber cartridge at the moment of inclusion and
after 24 h. Each hemoperfusion session lasted 2 h (PMX
group). Sequential organ failure assessment (SOFA) [25]
and Acute-Dialysis-Quality Initiative (ADQI)-RIFLE
[scoring system that deﬁnes three grades of increasing
severity of ARF (risk, injury, and failure, respectively, R,
I, and F) and two outcome variables (loss and end-stage
kidney disease, respectively, L and E)] [26] scores were
evaluated at T0 and T72. Amount and kind of catechol-
amine support were also recorded at T0 and T72.
Plasma and urine determinations
Blood and urine samples were collected at the time of
inclusion (T0) and 24 h (T24) and 72 h (T72) later. In the
PMX group, samples were also collected at the end of
each hemoperfusion (T2 and T26). Clinical variables
were followed for 28 days. Blood samples were stored at
-80C. Plasma levels of LPS were evaluated by Limulus
Amebocyte Lysate (LAL) kinetic test (Cambrex, Walk-
ersville, MD). Plasma concentrations of tumor necrosis
factor-a (TNF-(a) were determined by an enzyme-linked
immunoabsorbent assay (ELISA; R&D Systems, Minne-
apolis, MN). Urine samples were collected for the
evaluation of proteins and the tubular enzymes NAG (N-
acetyl-glucosaminidase), GGT (gamma-glutamyl trans-
peptidase), and AAP (Ala-Leu-Gly aminopeptidase). All
values were expressed as ratio to urine creatinine [17]t o
avoid the tubular concentration factor [27].
Kidney cell cytotoxicity and apoptosis
Human proximal tubular epithelial cells and glomerular
podocytes were isolated from the renal cortex and cul-
tured as previously described [28]. Cells were incubated
with plasmas obtained from the CONV group and the
1639PMX group. Plasma from healthy volunteers or vehicle
alone was used as controls. The cytotoxic effect of dif-
ferent plasmas was evaluated by a colorimetric assay
based on the ability of XTT sodium salts to bind to
mitochondrial dehydrogenases of viable cells [29].
Podocytes and tubular cell cultures were subjected to
terminal deoxynucleotidyltransferase (TdT)-mediated
dUTP nick end labeling (TUNEL) assay [29] to identify
chromatin fragmentation in apoptotic cells. In a pilot
study, that included ﬁve patients that matched study
inclusion and exclusion criteria, we found that the col-
lected plasma induced apoptosis in 45–50 cells per ﬁeld
of cultured tubular and podocytes. This trial was hence
designed to enroll 16 patients to demonstrate at least a
30% reduction in proapoptotic activity, with a 5% risk of
type I error and a power of 90%. Fas (CD95) was detected
by immunoﬂuorescence and by FACS analysis as previ-
ously described [4]. Bax and Bcl-2 family proteins were
investigated by Western blot [29]. The activity of cas-
pase-3, caspase-8, and caspase-9 was assessed by ELISA.
In selected experiments, tubular cells were seeded on
six-well plates and TNF-receptor 1 (TNF-R1) short
interfering RNA (siRNA) or relative control siRNA
(80 pM) was introduced according to manufacturer’s
instructions (Santa Cruz Biotech., Santa Cruz, CA). After
48 h, TNF-R1 knockdown was veriﬁed by RT-PCR,
immunoﬂuorescence, and Western blot analysis. Subse-
quently, engineered tubular cells were incubated with
different plasma and subjected to TUNEL assay.
Kidney cell functions
Transepithelial electrical resistance (TER) was used to
estimate alteration of selective cell polarity [30]. Perme-
ability was evaluated by diffusion of Trypan blue-albumin
complexes on podocyte monolayer. Adhesion to extra-
cellular matrixes and morphogenesis assay was studied as
previously described [30]. Expression of intercellular
adhesion molecules-1 (ICAM-1) and CD40 on tubular
epithelial cells was evaluated by cytoﬂuorimetric analy-
sis. Detection of ZO1, megalin, nephrin, and B7.1 was
performed by immunoﬂuorescence [31, 32].
Statistical analysis
The data were expressed as mean ± SD or median and
range when appropriate. Comparisons were performed
using the unpaired t test, the Mann–Whitney, the chi-
square and the Fisher exact test when appropriate. Com-
parison among different time points within each group
was evaluated using a two-way analysis of variance for
repeated measurements (ANOVA) with Newman–Keuls
correction; if signiﬁcant (P\0.05), values obtained at
different levels of exposure to plasma were compared
with T0 using the paired t test or Wilcoxon’s signed-rank
test when appropriate (Statview 5.0, CA).
Results
Twenty patients with Gram-negative infection and sepsis
were assessed for eligibility. One was excluded for HIV
infection, three for presence of two or more failing
organs. Sixteen consecutive patients were enrolled, eight
patients in the PMX-B group and eight in the CONV
group. Some of the results are available on the ESM.
Effects on clinical and biochemical parameters
On admission, all patients were treated according to the
Surviving Sepsis Campaign guidelines and required cat-
echolamine support. Patients were equally distributed for
age, gender, APACHE II, sites of infection, antibiotic
therapy and organ dysfunctions (Table 1). After 72 h,
SOFA decreased (P = 0.02) and RIFLE improved
(P = 0.04) in the PMX group, while it did not change in
the CONV group; ﬁve out of eight patients were weaned
from catecholamine support in the PMX group
(P = 0.02), whereas in the CONV group all patients but
one were still on catecholamines (Table 1). The need for
renal replacement therapy occurred in one patient in the
PMX group (17%) and in three patients (37%) in the
CONV group (P = 0.02). In the PMX group but not in
CONV group, a signiﬁcant reduction in plasmatic levels
of LPS and TNF-alpha was observed at T72.
Effect on cellular cytotoxicity and apoptosis
Compared to incubation with vehicle alone or healthy
plasma, septic plasma (concentration 5% diluted in nor-
mal culture medium) derived from both PMX and CONV
groups reduced the viability of glomerular podocytes (not
shown) and tubular cells, as detected by the XTT-based
assay (Figure 1, A and B in ESM). In the PMX group, a
signiﬁcant reduction of tubular injury was observed after
challenging with plasma collected at the end of both
PMX-B hemoperfusion sessions (PMX T2 and PMX T26)
and after 72 h of the enrollment in the study (PMX T72).
By contrast, in the CONV group, plasma-induced tubular
injury remained constant over time (Figure 1, A and B in
ESM).
Plasma frompatients of CONVT0andPMX T0groups
induced signiﬁcant tubular cell apoptosis, as detected by
TUNEL assay (Fig. 1a). While plasma-induced apoptosis
remained signiﬁcantly higher in the CONV T72 group, it
wassigniﬁcantlyreducedinthePMXT72groupcompared
to PMX T0. Furthermore, addition of 5 lg/ml PMX-B, a
1640dose found to signiﬁcantly inhibit LPS biological activity
without inducing tubular cell death, to the culture signiﬁ-
cantly reduced the proapoptotic activity of PMX T0,
CONV T0, and CONV T72 plasma but not of PMX T72
plasma.However,plasmafromthePMX-Bhemoperfusion
with or without the addition of Polymyxin-B did not com-
pletely abrogate the proapoptotic effect of plasma (Figure
1,C in ESM). In all apoptosis experiments, LPS (30 ng/ml)
was used as a positive control.
TNF-R1 knockdown by siRNA induced a signiﬁcant
decrease of tubular apoptosis at T0 and T72 either in
PMX or CONV group (Fig. 1b).
Activities of caspase-3, caspase-8, and caspase-9 were
signiﬁcantly increased in tubular cells after incubation
with PMX T0 and CONV T0 plasma (Fig. 2). All casp-
ases remained activated after incubation of tubular cells
with CONV T72 plasma. By contrast, we observed a
signiﬁcant reduction of all caspase activities after PMX
T72 plasma challenge.
Compared to controls, FACS and immunoﬂuorescence
demonstrated a marked upregulation of Fas expression in
presence of PMX T0 and CONV T0 plasma, which
remained upregulated after incubation of tubular cells
with CONV T72 plasma. A signiﬁcant decrease in Fas
expression was observed after incubation with PMX T72
plasma (Fig. 2). Moreover, tubular cells exposed to PMX
T72 plasma showed a signiﬁcant decrease of the ratio
between the mitochondrial proteins Bax and Bcl-2
(Fig. 2).
Effects on cellular function
After incubation with PMX T0, CONV T0, or CONV T72
plasmas, tubular cells exhibited signiﬁcantly lower TER
values in comparison to stimulation with vehicle alone or
Table 1 Patients’ demographic, clinical, and biochemical data
PMX CONV
Age (years) 61 ± 10 59 ± 13
Male N (%) 6 (75) 6 (75)
APACHE II 21.2 ± 3.6 20.4 ± 4.4
Site of infection N (%)
Abdominal 7 (87) 5(65)
Urinary tract 1 (13) 3(35)
Antibiotics N (%)
Glycopeptides 4 (50) 5 (62)
Aminoglycosides 3 (37) 4 (50)
SOFA score
T0 11 (13–7) 9 (20–7)
T72 5.5 (11–2)
a 10.5 (23–6)
d
RIFLE N (%)
Risk
T0 5 (62.5) 5 (62.5)
T72 2 (25) 2 (25)
Injury
T0 2 (25) 1 (12.5)
T72 0 1 (12.5)
Failure
T0 0 0
T72 0 1(12.5)
Risk + injury + failure
T0 7 (87) 6 (75)
T72 2 (25)
b 4 (50)
Patients on catecholamine N
(%)
T0 8 (100) 8(100)
T72 3 (37)
c 7 (87)
Noradrenaline (lg/kg/min)
T0 0.5 (1.0–0.1) 0.45 (0.8–0.08)
T72 0 (0.4–0)
a 0.12 (0.8–0)
LPS (pg/ml)
T0 187.83 ± 21.45 162.57 ± 37.87
T72 87.74 ± 19.45
a 184.63 ± 30.56
TNF-alpha (pg/ml)
T0 84.53 ± 19.85 76.53 ± 16.32
T72 21.34 ± 7.98
a 95.34 ± 19.64
Data are expressed as mean ± SD and median (range)
PMX polymyxin-B, CONV conventional, APACHE II acute phys-
iology and chronic health evaluation, SOFA sequential organ
failure assessment, RIFLE risk, injury, failure, loss of function, end
stage
a Wilcoxon Signed Rank test PMX: T0 versus T72, P = 0.02
b Fisher Exact test PMX: T0 versus T72, P = 0.04
c Fisher Exact test: PMX versus CONV at T72, P = 0.02
d Mann–Whitney test: PMX T72 versus CONV T72, P = 0.02
Fig. 1 a Evaluation of tubular apoptosis (TUNEL) induced by
incubation for 48 h with CONV or PMX plasmas in tubular cells.
All PMX and CONV plasmas induced a signiﬁcant increase of
tubular apoptosis (*P\0.05). Incubation of tubular cells with
PMX T72 plasma resulted in a signiﬁcant decrease of apoptosis
compared to PMX T0 plasma (
P\0.05). LPS (30 ng/mL) was
used as positive control. b Evaluation of tubular apoptosis
(TUNEL) in tubular cells subjected to short interfering RNA
(siRNA) for tumor necrosis factor-receptor 1 (TNF-R1) or for a
noncoding control after incubation with CONV and PMX plasma.
Compared to control siRNA, a signiﬁcant decrease of tubular
apoptosis was observed in siRNA TNF-R1 tubular cells incubated
with CONV and PMX plasma (*P\0.05). LPS (30 ng/mL) was
used as positive control
1641healthy plasma. By contrast, incubation with PMX T72
plasma induced a signiﬁcant increase of TER levels in
comparison to PMX T0, CONV T0, or CONV T72
(Figure 2, A in ESM).
Incubation of tubular cells with PMX T0, CONV T0,
or CONV T72 plasmas resulted in a signiﬁcant reduction
of cell adhesion to type IV collagen-coated, ﬁbronectin-
coated, and Matrigel-coated surfaces, which was signiﬁ-
cantly abated in presence of PMX T72 plasma (Figure 2,
B in ESM). Furthermore, we found that CONV plasmas
inhibited morphogenesis of tubular cells cultured onto
Matrigel and that PMX-B hemoperfusion restored proper
tubular formation (Figure 2, C in ESM).
Incubation with PMX T0 and CONV T0 plasmas
induced a signiﬁcant upregulation of the costimulatory
molecule CD40 and of the adhesion receptor ICAM-1 on
tubular cell surface, in comparison to exposure to vehicle
alone or healthy plasma. The overexpression of both
proteins was reduced after incubation with PMX T72
(Figure 3 in ESM).
Fig. 2 Top: Enzyme-linked
immunoabsorbent (ELISA)
evaluation of caspase-3,
caspase-8, and caspase-9
activities on tubular cells
cultured for 48 h with 5%
CONV or PMX plasma. PMX
T0 and CONV T0 and T72
plasmas induced a signiﬁcant
increase of all caspase activities
(*P\0.05 vs. healthy plasma).
A signiﬁcant decrease of all
caspase activities was found
with PMX T72 plasma
compared to PMX T0
(
P\0.05 PMX T72 vs. PMX
T0); however, caspase-3 and
caspase-9 activities remained
signiﬁcantly higher than healthy
plasma (*P\0.05 PMX T72
vs. healthy plasma). Middle:
Representative images of FACS
and immunoﬂuorescence
(insets) analysis of Fas (CD95)
expression on tubular cell
surface after exposure to CONV
or PMX plasma. PMX T0 and
CONV T0 and T72 plasmas all
induced a marked upregulation
of Fas, which was signiﬁcantly
reduced in presence of PMX
T72 plasma. 9400
magniﬁcation. Bottom:
Representative western blot
analysis of the mitochondrial
proteins Bax and Bcl2 in
tubular cells exposed to CONV
or PMX plasma, and related
densitometric analysis
expressed as Bax/Bcl2 ratio.
PMX T0, CONV T0, and
CONV T72 plasmas induced a
marked upregulation of the
Bax/Bcl2 ratio that was reduced
in the presence of PMX T72
plasma. (Lane 1 Vehicle; Lane
2 Healthy; Lane 3 PMX T0;
Lane 4 PMX T72; Lane 5
CONV T0; Lane 6 CONV T72).
Beta-actin was used as
reference for protein loading
1642Compared to incubation with vehicle or healthy
plasma, we observed an intense downregulation of meg-
alin and ZO1 after challenging with PMX T0, CONV T0,
or CONV T72 plasmas (Fig. 3 and Figure 4 in ESM). By
contrast, PMX T72 plasma did not induce alterations of
megalin and ZO1 expression.
Incubation with PMX T0, CONV T0, or CONV T72
plasmas induced a signiﬁcant reduction of TER (Figure 5,
A in ESM) and a concomitant increase of permeability to
albumin (Figure 5, B in ESM) in cultured podocytes.
Additionally, PMX T72 plasma inhibited the reduction of
TER and albumin diffusion induced by septic plasma. The
expression of nephrin was markedly downregulated in the
presence of PMX T0, CONV T0, or CONV T72 plasmas
(Fig. 4 and Figure 5C in ESM). In contrast, PMX T72
plasma did not alter nephrin expression.
Podocytes expressed basal levels of B7.1 in the pres-
ence of vehicle alone or healthy plasma. B7.1 was
markedly upregulated only after incubation with PMX
T0, CONV T0, or CONV T72 plasmas but not with PMX
T72 plasma (Fig. 4 and Figure 6 in ESM).
Furthermore, in correlation to the described results on
kidney cell functions, at T72, the PMX group showed a
signiﬁcant reduction of proteinuria and of tubular enzymes
not detectable in the CONV group (Figure 7 in ESM).
Discussion
Direct hemoperfusion through a column of immobilized
PMX-B has been proposed to prevent kidney dysfunction
in patients with Gram-negative sepsis [8, 33]. The present
study shows that the improvement of renal function
observed after PMX-B hemoperfusion might be associ-
ated with the attenuation of the proapoptotic activity
exerted by circulating factors present in plasma of
patients with Gram-negative sepsis. The present study
excluded patients with septic shock and/or sepsis with two
or more failing organs, since activated protein C might be
indicated for these patients and data on the interaction
between activated protein C and extracorporeal PMX-B
treatment are not currently available [24].
ARF, one of the most frequent organ dysfunction in
sepsis [1], has been closely linked to apoptosis [34]. A
recent study shows that in Gram-negative sepsis, LPS can
directly cause apoptosis of tubular cells through a Fas-
mediated and caspase-mediated pathways; increased
plasma levels of soluble Fas has been described in septic
patients [4]. Additionally, experimental models of sepsis
have shown that increased caspase activation is associated
with the presence of ARF [5]. We found that the reduced
proapoptotic activity of plasma on renal tubular cells
caused by PMX-B hemoperfusion was mediated by the
reduction of Fas upregulation, caspase activity, and Bax/
Bcl2 protein ratio. These results suggest that PMX-B
treatment of septic patients decreases the apoptosis of
renal epithelial cells through the alteration of the death-
receptor and mitochondrial-associated apoptotic signaling
pathways. However, PMX-B hemoperfusion did not
completely abrogate the proapoptotic effect of septic
plasma on tubular cells, suggesting that circulating
mediators other than LPS may be involved in kidney
injury. Cunningham and coworkers [36] demonstrated
that TNF-alpha is a key mediator of LPS-induced kidney
injury acting through TNF-R1 receptor. In this study, we
conﬁrmed that PMX-B hemoperfusion induced a signiﬁ-
cant decrease of plasmatic levels of LPS and TNF-a. Even
though PMX-B can alter plasmatic lipoprotein proﬁle
therefore modulating LPS clearance [37], the results of
this study showed a strong correlation between the
reduced levels of LPS and the plasma-induced tubular
apoptosis. Moreover, we found that TNF-R1 knockdown
of tubular cells by siRNA signiﬁcantly reduced plasma-
induced apoptosis also after PMX-B hemoperfusion,
conﬁrming a potential prominent role of TNF-a in sepsis-
related kidney injury.
Fig. 3 Average ﬂuorescence expression of megalin and ZO1 on
tubular cells. PMX T0, CONV T0, and CONV T72 plasmas
induced a marked reduction of megalin and ZO1 expression
(*P\0.05 vs. healthy plasma). After incubation with PMX T72
plasma, a signiﬁcant increase of megalin and ZO1 staining was
observed (
P\0.05 PMX T72 vs. PMX T0)
Fig. 4 Average ﬂuorescence expression of nephrin and B7.1 on
glomerularpodocytes.PMXT0,CONVT0,andCONVT72plasmas
induced a marked reduction of nephrin and the upregulation of B7.1
(*P\0.05 vs. healthy plasma). After incubation with PMX T72
plasma,anincreasedexpressionofnephrinandareducedstainingfor
B7.1 was observed (
P\0.05 PMX T72 vs. PMX T0)
1643Recent clinical studies showed that in patients with
Gram-negative sepsis, compared to conventional
treatment, hemoperfusion through a PMX-B cartridge
signiﬁcantly decreases vasopressors requirement [9] and
reduces the need for continuous renal replacement therapy
(CRRT) [9, 12]. Consistent with previous studies, we
observed that 72 h after entering the study, patients
included in the PMX group had a signiﬁcant reduction of
catecholamine requirement, an improvement of SOFA
and RIFLE scores, and a signiﬁcant decrease in RRT
requirement as compared to the CONV group. In septic
patients with endotoxemia, Nakamura and coworkers
recently showed a relevant improvement in renal function
after treatment with PMX-B hemoperfusion; this func-
tional improvement was associated to a signiﬁcant
decrease of urine NAG/creatinine ratio, albuminuria, and
plasma endotoxin level [12, 35]. Consistently, we found
that 72 h after entering the study, the PMX group showed
a signiﬁcant reduction of the urinary protein-to-creatinine
ratio and of the tubular enzymes GGT, NAG, AAP.
The alteration of cellular permeability and polarity can
contribute to kidney dysfunction [36, 37]. In this study,
we show that in tubular cells, the plasma taken from the
patients of the CONV group at T0 and T72 and of the
PMX group at T0 induced a marked decrease of the tight
junction molecule ZO1. By contrast, plasma of patients
treated with PMX-B after 72 h did not exhibit this effect.
Moreover, while the plasma taken from patients of the
CONV group turned down the expression of megalin (the
endocytic receptor that regulates the physiological reab-
sorption of glomerular-ﬁltered low molecular weight
proteins), the plasma drawn from patients treated with
PMX-B left unchanged in its expression. These results
suggest that PMX-B treatment may remove factors able to
alter physiologic kidney cell polarity and protein
handling.
Microalbuminuria is an early index of impairment of
glomerular permeability in septic patients [38]. We
observed that albumin diffusion across podocyte mono-
layer decreased only in the presence of plasma collected
after PMX-B treatment. This phenomenon was associated
with the maintenance of a normal expression of nephrin, a
slit diaphragm protein known to modulate glomerular
permeability, that signiﬁcantly downregulated after
incubation with CONV T0, CONV T72, and PMX T0
plasma. Moreover, CONV T0, CONV T72, and PMX T0
plasma induced the upregulation of B7.1, a costimulatory
molecule, which is known to be induced by LPS through
TLR-4 signaling [32]. This effect was almost completely
blunted in presence of plasma collected after PMX-B
hemoperfusion, thus suggesting a further protective action
of this depurative treatment on the development of pro-
teinuria and in the extension of renal injury.
In conclusion, this study demonstrates that extracor-
poreal therapy with PMX-B reduces the proapoptotic
activity of the plasma of septic patients on cultured cell.
These data conﬁrm the role of apoptosis in the develop-
ment of sepsis-related acute renal dysfunction and
indicate a putative protective effect of PMX-B hemo-
perfusion in the early prevention of kidney injury.
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